Premium
Circulating serum and plasma levels of micro‐RNA in type‐1 diabetes in children and adolescents: A systematic review and meta‐analysis
Author(s) -
Margaritis Kosmas,
MargioulaSiarkou Georgia,
MargioulaSiarkou Chrysoula,
Petousis Stamatios,
Kotanidou Eleni P.,
Christoforidis Athanasios,
Pavlou Evangelos,
GalliTsinopoulou Assimina
Publication year - 2021
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13510
Subject(s) - meta analysis , medicine , type 1 diabetes , diabetes mellitus , microrna , population , incidence (geometry) , systematic review , medline , bioinformatics , inclusion and exclusion criteria , endocrinology , pathology , biology , genetics , biochemistry , alternative medicine , physics , environmental health , optics , gene
Background Type 1 diabetes mellitus (T1DM) is a complex metabolic disorder characterized by hyperglycaemia, with constantly increasing incidence in paediatric population. The discovery of new molecules, such as microRNAs, and their possible interactions with T1DM create novel aspects in the diagnosis of the disease. Methods This systematic review and meta‐analysis adhered to PRISMA guidelines. MEDLINE, SCOPUS, Cochrane CENTRAL and Clinicaltrials.gov. were searched up to 20 April 2020. Inclusion criteria for individual studies were quantification of microRNAs in serum/plasma samples and study groups consisting of children and adolescents with T1DM and healthy controls. Primary outcome of the study was the qualitative expression of microRNAs between the two groups. Statistical analysis was performed with Comprehensive Meta‐Analysis Software v3.0. Methodological quality of included studies was assessed using Newcastle‐Ottawa scale. Results A total of 484 studies were retrieved from the initial search of the databases. These were subsequently limited to seven included studies. Seven microRNAs demonstrated contrasting expression between the two groups, with two of them showing significant overexpression in T1DM group (miR‐181:95% CI: 0.429 to 1.341 P < .001, miR‐210:95% CI: 0.381 to 0.852, P < .001) and one micro‐RNA being significantly overexpressed in control group (miR‐375:95% CI: 0.293 to 1.459, P = .003). Conclusion A total of three micro‐RNA molecules appeared to have a significantly different expression in T1DM patients, serving as a possible diagnostic panel of biomarkers. These findings may contribute as reference for future research to further support the use of microRNAs as a novel diagnostic tool in T1DM.